Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Next Previous
Trial Profile

KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mivocabtagene autoleucel (Primary)
  • Indications Lupus nephritis
  • Focus Adverse reactions
  • Acronyms KYSA-1
  • Sponsors Kyverna Therapeutics

Most Recent Events

  • 29 Oct 2025 Planned End Date changed from 1 Aug 2026 to 1 Aug 2027.
  • 29 Oct 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Aug 2026.
  • 10 Jun 2025 Planned number of patients changed from 12 to 32.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top